{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T20:01:12Z","timestamp":1776801672262,"version":"3.51.2"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100017266","name":"Navarra Government","doi-asserted-by":"publisher","award":["20\/21"],"award-info":[{"award-number":["20\/21"]}],"id":[{"id":"10.13039\/501100017266","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002924","name":"Federaci\u00f3n Espa\u00f1ola de Enfermedades Raras","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002924","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["PI22\/01400"],"award-info":[{"award-number":["PI22\/01400"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.pnpbp.2025.111336","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T17:51:48Z","timestamp":1742406708000},"page":"111336","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Bioenergetic markers in cerebrospinal fluid in first-episode psychosis: Are they predictors of early antipsychotic response and 1-year outcomes?"],"prefix":"10.1016","volume":"138","author":[{"given":"Eloi","family":"Gin\u00e9-Serv\u00e9n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ester","family":"Boix-Quintana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Ballesteros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Dav\u00ed-Loscos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolau","family":"Guanyabens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia","family":"Casado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Mart\u00ednez-Ram\u00edrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedicto","family":"Crespo-Facorro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel J.","family":"Cuesta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Labad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2025.111336_bb0005","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1001\/archpsyc.60.12.1228","article-title":"Delayed-onset hypothesis of antipsychotic action","volume":"60","author":"Agid","year":"2003","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.pnpbp.2025.111336_bb0010","first-page":"93","article-title":"The \u201cdelayed onset\u201d of antipsychotic action--an idea whose time has come and gone","volume":"31","author":"Agid","year":"2006","journal-title":"J. Psychiatry Neurosci."},{"key":"10.1016\/j.pnpbp.2025.111336_bb0015","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.euroneuro.2012.10.005","article-title":"Early prediction of clinical and functional outcome in schizophrenia","volume":"23","author":"Agid","year":"2013","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2025.111336_bb0020","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/0006-3223(94)00383-1","article-title":"Plasma homovanillic acid levels and therapeutic outcome in schizophrenics: comparisons of neuroleptic-naive first-episode patients and patients with disease exacerbation due to neuroleptic discontinuance","volume":"38","author":"Akiyama","year":"1995","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2025.111336_bb0025","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.schres.2010.10.013","article-title":"Predictors of recovery from psychosis","volume":"125","author":"Albert","year":"2011","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pnpbp.2025.111336_bb0030","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1017\/S0033291711001504","article-title":"Road to full recovery: longitudinal relationship between symptomatic remission and psychosocial recovery in first-episode psychosis over 7.5 years","volume":"42","author":"\u00c1lvarez-Jim\u00e9nez","year":"2012","journal-title":"Psychol. Med."},{"key":"10.1016\/j.pnpbp.2025.111336_bb0035","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.schres.2013.07.031","article-title":"Predictors of recovery in first episode psychosis: the OPUS cohort at 10year follow-up","volume":"150","author":"Austin","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pnpbp.2025.111336_bb0040","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1600-0447.1990.tb01360.x","article-title":"The list of threatening experiences: the reliability and validity of a brief life events questionnaire","volume":"82","author":"Brugha","year":"1990","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.pnpbp.2025.111336_bb0045","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0920-9964(93)90060-V","article-title":"Plasma homovanillic acid and treatment response in a large group of schizophrenic patients\u2606","volume":"10","author":"Chang","year":"1993","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pnpbp.2025.111336_bb0050","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1017\/S0033291716001902","article-title":"Impaired glucose tolerance in first-episode drug-na\u00efve patients with schizophrenia: relationships with clinical phenotypes and cognitive deficits","volume":"46","author":"Chen","year":"2016","journal-title":"Psychol. Med."},{"key":"10.1016\/j.pnpbp.2025.111336_bb0055","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.psychres.2017.11.053","article-title":"Responsiveness of the personal and social performance scale in patients with schizophrenia","volume":"260","author":"Chiu","year":"2018","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.pnpbp.2025.111336_bb0060","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1176\/appi.ajp.160.11.2063","article-title":"Early prediction of antipsychotic response in schizophrenia","volume":"160","author":"Correll","year":"2003","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2025.111336_bb0065","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/jamapsychiatry.2018.0623","article-title":"Comparison of early intervention services vs treatment as usual for early-phase psychosis","volume":"75","author":"Correll","year":"2018","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.pnpbp.2025.111336_bb0070","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/brain\/aww297","article-title":"Connectomic correlates of response to treatment in first-episode psychosis","volume":"140","author":"Crossley","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.pnpbp.2025.111336_bb0075","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3389\/fncel.2016.00018","article-title":"Proteomics research in schizophrenia","volume":"10","author":"Davalieva","year":"2016","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.pnpbp.2025.111336_bb0080","doi-asserted-by":"crossref","DOI":"10.1038\/s41380-023-02065-4","article-title":"Insulin effects on core neurotransmitter pathways involved in schizophrenia neurobiology: a meta-analysis of preclinical studies. Implications for the treatment","author":"de Bartolomeis","year":"2023","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2025.111336_bb0085","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.schres.2014.02.005","article-title":"Cytokine alterations in first-episode schizophrenia patients before and after antipsychotic treatment","volume":"154","author":"de Witte","year":"2014","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pnpbp.2025.111336_bb0090","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1017\/S0033291717000435","article-title":"Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors","volume":"47","author":"Demjaha","year":"2017","journal-title":"Psychol. Med."},{"key":"10.1016\/j.pnpbp.2025.111336_bb0095","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.pnpbp.2014.01.001","article-title":"Activation of Th17 cells in drug na\u00efve, first episode schizophrenia","volume":"51","author":"Ding","year":"2014","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatr."},{"key":"10.1016\/j.pnpbp.2025.111336_bb0100","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.3758\/BRM.41.4.1149","article-title":"Statistical power analyses using G*power 3.1: tests for correlation and regression analyses","volume":"41","author":"Faul","year":"2009","journal-title":"Behav. Res. Methods"},{"key":"10.1016\/j.pnpbp.2025.111336_bb0105","series-title":"Structured Clinical Interview for DSM-IV axis I Disorders","author":"First","year":"1994"},{"key":"10.1016\/j.pnpbp.2025.111336_bb0110","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1176\/appi.ajp.2009.09060802","article-title":"International consensus study of antipsychotic dosing","volume":"167","author":"Gardner","year":"2010","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2025.111336_bb0115","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1159\/000337739","article-title":"Antipsychotic response in the First week predicts later efficacy","volume":"66","author":"Giegling","year":"2012","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.pnpbp.2025.111336_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2021.110424","article-title":"Routine cerebrospinal fluid parameters as biomarkers in first-episode psychosis: a prospective observational study","volume":"112","author":"Gin\u00e9-Serv\u00e9n","year":"2022","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatr."},{"key":"10.1016\/j.pnpbp.2025.111336_bb0125","article-title":"Psychosocial stress moderates the relationship between cerebrospinal fluid lactate dehydrogenase and the duration of untreated psychosis in first-episode psychosis","volume":"15","author":"Gin\u00e9-Serv\u00e9n","year":"2024","journal-title":"Front. Psychol."},{"key":"10.1016\/j.pnpbp.2025.111336_bb0130","doi-asserted-by":"crossref","first-page":"638","DOI":"10.3390\/medicina56120638","article-title":"A synthetic literature review on the Management of Emerging Treatment Resistance in First episode psychosis: can we move towards precision intervention and individualised care?","volume":"56","author":"Griffiths","year":"2020","journal-title":"Medicina (B. Aires)"},{"key":"10.1016\/j.pnpbp.2025.111336_bb0135","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1212\/WNL.0000000000012191","article-title":"Clinical, Neuroimmunologic, and CSF investigations in First episode psychosis","volume":"97","author":"Guasp","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.pnpbp.2025.111336_bb0140","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/mp.2009.81","article-title":"Increased levels of circulating insulin-related peptides in first-onset, antipsychotic na\u00efve schizophrenia patients","volume":"15","author":"Guest","year":"2010","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2025.111336_bb0145","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.psyneuen.2010.12.018","article-title":"Altered levels of circulating insulin and other neuroendocrine hormones associated with the onset of schizophrenia","volume":"36","author":"Guest","year":"2011","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.pnpbp.2025.111336_bb0150","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.schres.2019.02.003","article-title":"Longitudinal trajectory of early functional recovery in patients with first episode psychosis","volume":"209","author":"Hall","year":"2019","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pnpbp.2025.111336_bb0155","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A RATING SCALE FOR DEPRESSION","volume":"23","author":"Hamilton","year":"1960","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.pnpbp.2025.111336_bb0160","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1038\/mp.2010.71","article-title":"Impaired glycolytic response in peripheral blood mononuclear cells of first-onset antipsychotic-naive schizophrenia patients","volume":"16","author":"Herberth","year":"2011","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2025.111336_bb0165","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1192\/bjp.bp.114.153486","article-title":"Investigating trajectories of social recovery in individuals with first-episode psychosis: a latent class growth analysis","volume":"207","author":"Hodgekins","year":"2015","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2025.111336_bb0170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030327","article-title":"Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia","volume":"3","author":"Holmes","year":"2006","journal-title":"PLoS Med."},{"key":"10.1016\/j.pnpbp.2025.111336_bb0175","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1093\/schbul\/sbac098","article-title":"Cerebrospinal fluid and blood biomarkers of Neuroinflammation and blood-brain barrier in psychotic disorders and individually matched healthy controls","volume":"48","author":"Jeppesen","year":"2022","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.pnpbp.2025.111336_bb0180","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1176\/appi.ajp.162.5.939","article-title":"Evidence for onset of antipsychotic effects within the First 24 hours of treatment","volume":"162","author":"Kapur","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2025.111336_bb0185","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1097\/00004583-199707000-00021","article-title":"Schedule for affective disorders and schizophrenia for school-age children-present and lifetime version (K-SADS-PL): initial reliability and validity data","volume":"36","author":"Kaufman","year":"1997","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.pnpbp.2025.111336_bb0190","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.pnpbp.2025.111336_bb0195","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.schres.2008.02.021","article-title":"Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia\u2606","volume":"102","author":"Kinon","year":"2008","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pnpbp.2025.111336_bb0200","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/npp.2009.164","article-title":"Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia","volume":"35","author":"Kinon","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2025.111336_bb0205","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1017\/S0033291716002014","article-title":"Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses","volume":"46","author":"Lally","year":"2016","journal-title":"Psychol. Med."},{"key":"10.1016\/j.pnpbp.2025.111336_bb0210","first-page":"117","article-title":"Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics","volume":"9","author":"Lally","year":"2016","journal-title":"Pharmgenomics. Pers. Med."},{"key":"10.1016\/j.pnpbp.2025.111336_bb0215","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/01.jcp.0000150226.84371.76","article-title":"Dopamine D3 receptor Ser9Gly polymorphism and risperidone response","volume":"25","author":"Lane","year":"2005","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2025.111336_bb0220","doi-asserted-by":"crossref","first-page":"352","DOI":"10.4088\/JCP.v68n0301","article-title":"Early prediction of antipsychotic nonresponse among patients with schizophrenia","volume":"68","author":"Leucht","year":"2007","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.pnpbp.2025.111336_bb0225","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/mpr.1379","article-title":"Young mania rating scale: how to interpret the numbers? Determination of a severity threshold and of the minimal clinically significant difference in the EMBLEM cohort","volume":"22","author":"Lukasiewicz","year":"2013","journal-title":"Int. J. Methods Psychiatr. Res."},{"key":"10.1016\/j.pnpbp.2025.111336_bb0230","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.schres.2019.12.011","article-title":"Depressive symptoms during first episode psychosis and functional outcome: a systematic review and meta-analysis","volume":"218","author":"McGinty","year":"2020","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pnpbp.2025.111336_bb0235","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/schbul\/sbv028","article-title":"Cortisol and inflammatory biomarkers predict poor treatment response in First episode psychosis","volume":"41","author":"Mondelli","year":"2015","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.pnpbp.2025.111336_bb0240","article-title":"Glycated Haemoglobin is associated with poorer cognitive performance in patients with recent-onset psychosis","volume":"11","author":"Montalvo","year":"2020","journal-title":"Front. Psychol."},{"key":"10.1016\/j.pnpbp.2025.111336_bb0245","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1093\/schbul\/sbab145","article-title":"Long-term outcomes of First-admission psychosis: a naturalistic 21-year follow-up study of symptomatic, functional and personal recovery and their baseline predictors","volume":"48","author":"Peralta","year":"2022","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.pnpbp.2025.111336_bb0250","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.psychres.2016.04.097","article-title":"The predictive value of early treatment response in antipsychotic-naive patients with first-episode psychosis: haloperidol versus olanzapine","volume":"241","author":"Rasmussen","year":"2016","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.pnpbp.2025.111336_bb0255","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1056\/NEJMcibr1503558","article-title":"Inhibition of lactate dehydrogenase to treat epilepsy","volume":"373","author":"Rho","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pnpbp.2025.111336_bb0260","article-title":"Neurocognition and duration of psychosis: a 10-year follow-up of First-episode patients","volume":"sbv083","author":"Rund","year":"2015","journal-title":"Schizophr. Bull."},{"issue":"80","key":"10.1016\/j.pnpbp.2025.111336_bb0265","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1126\/science.aaa1299","article-title":"Targeting LDH enzymes with a stiripentol analog to treat epilepsy","volume":"347","author":"Sada","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.pnpbp.2025.111336_bb0270","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1176\/appi.ajp.2015.14101329","article-title":"Early improvement as a predictor of later response to antipsychotics in schizophrenia: a diagnostic test review","volume":"172","author":"Samara","year":"2015","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2025.111336_bb0275","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.euroneuro.2022.11.011","article-title":"Relapse, cognitive reserve, and their relationship with cognition in first episode schizophrenia: a 3-year follow-up study","volume":"67","author":"S\u00e1nchez-Torres","year":"2023","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2025.111336_bb0280","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cpr.2017.09.007","article-title":"Predictors of functional recovery in first-episode psychosis: a systematic review and meta-analysis of longitudinal studies","volume":"58","author":"Santesteban-Echarri","year":"2017","journal-title":"Clin. Psychol. Rev."},{"key":"10.1016\/j.pnpbp.2025.111336_bb0285","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/YCO.0000000000000535","article-title":"Ketogenic diet for schizophrenia","volume":"32","author":"Sarnyai","year":"2019","journal-title":"Curr. Opin. Psychiatr."},{"key":"10.1016\/j.pnpbp.2025.111336_bb0290","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1176\/appi.ajp.2015.14121571","article-title":"Baseline striatal functional connectivity as a predictor of response to antipsychotic drug treatment","volume":"173","author":"Sarpal","year":"2016","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2025.111336_bb0295","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.euroneuro.2010.10.003","article-title":"Predictors of response and remission in the acute treatment of first-episode schizophrenia patients \u2014 is it all about early response?","volume":"21","author":"Schennach-Wolff","year":"2011","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2025.111336_bb0300","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2012.3","article-title":"Identification of blood-based molecular signatures for prediction of response and relapse in schizophrenia patients","volume":"2","author":"Schwarz","year":"2012","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.pnpbp.2025.111336_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2024.115866","article-title":"Ketogenic diet intervention on metabolic and psychiatric health in bipolar and schizophrenia: a pilot trial","volume":"335","author":"Sethi","year":"2024","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.pnpbp.2025.111336_bb0310","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1192\/bjp.2021.61","article-title":"Rates of treatment-resistant schizophrenia from first-episode cohorts: systematic review and meta-analysis","volume":"220","author":"Siskind","year":"2022","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2025.111336_bb0315","series-title":"Multilevel Analysis: An Introduction to Basic and Advanced Multilevel Modeling","author":"Snijders","year":"1999"},{"key":"10.1016\/j.pnpbp.2025.111336_bb0320","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.psychres.2010.11.017","article-title":"Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis","volume":"187","author":"Stauffer","year":"2011","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.pnpbp.2025.111336_bb0325","doi-asserted-by":"crossref","DOI":"10.1192\/bjo.2020.89","article-title":"Prevalence of treatment resistance and clozapine use in early intervention services","volume":"6","author":"Stokes","year":"2020","journal-title":"BJPsych. Open"},{"key":"10.1016\/j.pnpbp.2025.111336_bb0330","doi-asserted-by":"crossref","DOI":"10.1093\/schbul\/sbac201","article-title":"Association of Complement and Coagulation Pathway Proteins with Treatment Response in First-episode psychosis: a longitudinal analysis of the OPTiMiSE clinical trial","author":"Susai","year":"2023","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.pnpbp.2025.111336_bb0335","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1093\/schbul\/sbq126","article-title":"Magnetic resonance imaging predictors of treatment response in First-episode schizophrenia","volume":"38","author":"Szeszko","year":"2012","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.pnpbp.2025.111336_bb0340","doi-asserted-by":"crossref","first-page":"424","DOI":"10.2174\/1570159X21666221118164612","article-title":"Early efficacy of antipsychotic medications at week 2 predicts subsequent responses at week 6 in a large-scale randomized controlled trial","volume":"21","author":"Tang","year":"2023","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.pnpbp.2025.111336_bb0345","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1001\/jamapsychiatry.2019.0304","article-title":"Association of Insulin Resistance with Schizophrenia Polygenic Risk Score and Response to antipsychotic treatment","volume":"76","author":"Tomasik","year":"2019","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.pnpbp.2025.111336_bb0350","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.schres.2014.03.005","article-title":"Cytokine function in medication-naive first episode psychosis: a systematic review and meta-analysis","volume":"155","author":"Upthegrove","year":"2014","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pnpbp.2025.111336_bb0355","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the global burden of disease study 2019","volume":"396","author":"Vos","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.pnpbp.2025.111336_bb0360","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.schres.2012.01.031","article-title":"Searching for a consensus five-factor model of the positive and negative syndrome scale for schizophrenia","volume":"137","author":"Wallwork","year":"2012","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pnpbp.2025.111336_bb0365","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1192\/bjp.133.5.429","article-title":"A rating scale for mania: reliability, validity and sensitivity","volume":"133","author":"Young","year":"1978","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2025.111336_bb0370","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1093\/schbul\/sbv116","article-title":"Association of a Schizophrenia Risk Variant at the DRD2 locus with antipsychotic treatment response in First-episode psychosis","volume":"41","author":"Zhang","year":"2015","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.pnpbp.2025.111336_bb0375","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.jad.2013.04.028","article-title":"Severity classification on the Hamilton depression rating scale","volume":"150","author":"Zimmerman","year":"2013","journal-title":"J. Affect. Disord."}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584625000909?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584625000909?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T15:30:23Z","timestamp":1745854223000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584625000909"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":75,"alternative-id":["S0278584625000909"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2025.111336","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bioenergetic markers in cerebrospinal fluid in first-episode psychosis: Are they predictors of early antipsychotic response and 1-year outcomes?","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2025.111336","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111336"}}